Skip to main content

This job has expired

You will need to login before you can apply for a job.

Senior Process Engineer, Nucleic Acid Process Sciences

Employer
Intellia Therapeutics
Location
Cambridge, MA, United States
Start date
Jan 14, 2021

View more

Discipline
Engineering, Process Engineer, Manufacturing & Production, Process
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Genetown

Job Details

Our Mission: Developing curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

At Intellia, we are committed to solving the complex challenges of making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to create novel engineered cell therapies for immuno-oncological and autoimmune diseases.

Job Description:

Intellia is seeking a highly skilled and motivated Sr. Process Engineer to join our Nucleic Acid Process Sciences team. The successful applicant will have a strong background in scale-up, process development, and manufacture of nucleic acid-based APIs. The candidate will focus on developing and implementing scalable and robust processes related to the enzymatic synthesis of mRNAs. In addition, the role will help lead late-stage process development activities for lead clinical and pre-clinical programs through process robustness/characterization studies, understanding product quality, and helping to refine the product control strategy. The successful candidate must be able to work in a fast paced and highly dynamic environment.

Responsibilities:
  • Optimization and process limit evaluation of clinical scale mRNA purification using appropriate principals of process optimization (i.e. DoE).
  • Drive mRNA process scale up and development for later stage clinical manufacturing.
  • Lead experiments to confirm robust process performance.
  • Lock the process and define critical process parameters.
  • Explore, develop, and scale-up novel enzymatic processes and nucleic acid purifications
  • Develop MBRs and draft process reports.
  • Provide high quality data and ELN documentation to drive decision making within CMC teams.
  • Communicate research and development findings with internal teams and externally to CDMOs in tech transfer efforts.
  • Operate and maintain multiple laboratory instruments.

Qualifications:
  • Bachelor's Degree in Biochemistry, Chemical or Biochemical Engineering or related field with 10+ years of industry experience, or MS with at least 7+ years of industry experience.
  • Able to execute and develop MBRs for mRNA production.
  • Experience in purification and process development for biomacromolecules (e.g. mRNA, DNA).
  • Proficiency with relevant purification and analytical technologies and instrumentation.
  • Experience in process scale up and technical transfer.
  • Proficiency with Design of Experiment and process optimization tools
  • Experience with mRNA purification and in vitro transcription at scale is highly desirable, and GMP experience is a plus.
  • Organized, detail-oriented, and a self-starter who continuously seeks innovative solutions.
  • Team work, versatility, and strong problem solving/analytical skills are required.
  • Excellent verbal and written communication skills.

#LI-KO1

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert